Document is current
Any future updates will be listed below
-
Authors
Takeshima, Takao https://orcid.org/0000-0003-2678-6956
Matsumori, Yasuhiko https://orcid.org/0000-0001-5852-0146
Danno, Daisuke https://orcid.org/0000-0003-3737-4754
Takizawa, Tsubasa https://orcid.org/0000-0003-2605-7200
Ueda, Kaname https://orcid.org/0000-0003-1967-9829
Cai, Zhihong https://orcid.org/0000-0002-3431-197X
Hashimoto, Chie https://orcid.org/0009-0008-0227-8993
Katagiri, Hideaki
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
Eli Lilly Japan
- License Information
-
More Information
Article History
Received: 29 December 2025
Accepted: 26 March 2026
First Online: 22 April 2026
Declarations
:
: Takao Takeshima served on the speakers’ bureau for Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd.; received research funding/collaborative research expenses from AbbVie G.K., Amgen K.K., Eli Lilly Japan K.K., Eisai Co., Ltd., Lundbeck Japan K.K., and Pfizer Japan Inc.; and served as an advisor to Hedgehog MedTech, Inc., Sawai Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Yasuhiko Matsumori received personal consultancy fees from Amgen K.K., Astellas Pharma Inc., BioPharma K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Daisuke Danno received advisory fees from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Lundbeck; and honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Tsubasa Takizawa is a consultant/adviser and/or serves on an advisory board for Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., AbbVie G.K., and Teijin Pharma Ltd. He received speaker honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., and Sawai Pharmaceutical Co., Ltd., a grant from Pfizer Japan Inc., and research funding from Eli Lilly Japan K.K. and Tsumura & Co., outside the submitted work. Kaname Ueda, Zhihong Cai, Chie Hashimoto, and Hideaki Katagiri are employees of Eli Lilly Japan K.K. and may own stock/stock options of Eli Lilly and Company.
: Each participating site in Japan obtained study approval from the site-specific ethics review committee. This study was conducted in accordance with the Declaration of Helsinki (1964) and its later amendments and Good Pharmacoepidemiology Practices. All applicable Japanese laws and regulations were followed. All participants provided informed consent and agreed to participate in the study.
